NuPathe Overview
- Year Founded
-
2005
- Status
-
Acquired/Merged
- Employees
-
14
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$268M
NuPathe General Information
Description
Developer of therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The company's flagship product is Zeuity a transdermal system patch for the acute treatment of migraine. The company also has developed a pipeline based on its biodegradable implant technology enabling delivery of therapeutic levels of medication over a period of months with a single dose.
Contact Information
Corporate Office
- 227 Washington Street
- Suite 200
- Conshohocken, PA 19428
- United States
Corporate Office
- 227 Washington Street
- Suite 200
- Conshohocken, PA 19428
- United States
NuPathe Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 24-Feb-2014 | $268M | Completed | Generating Revenue | ||
| 10. Merger/Acquisition | 18-Dec-2013 | Cancelled | Generating Revenue | |||
| 9. Debt - General | 30-Jun-2013 | Completed | ||||
| 8. Debt - General | 31-Mar-2013 | Completed | ||||
| 7. PIPE | 23-Oct-2012 | Completed | Generating Revenue | |||
| 6. Debt - General | 14-Jun-2011 | Completed | Clinical Trials - Phase 3 | |||
| 5. IPO | 06-Aug-2010 | Completed | Clinical Trials - Phase 3 | |||
| 4. Debt - General | 23-Apr-2010 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 24-Jul-2008 | $33.6M | $49.9M | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | 13-Sep-2006 | $15.7M | $16.2M | Completed | Product Development |
NuPathe Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
NuPathe Comparisons
Industry
Financing
Details
NuPathe Competitors (2)
One of NuPathe’s 2 competitors is BioCryst Pharmaceuticals, a Corporation company based in Durham, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals | Corporation | Durham, NC | ||||
| Nabriva Therapeutics | Formerly VC-backed | Dublin, Ireland |
NuPathe Patents
NuPathe Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2014078517-A1 | Detection of presence and alignment of a therapeutic agent in an iontophoretic drug delivery device | Inactive | 14-Nov-2012 | ||
| WO-2014078517-A8 | Detection of presence and alignment of a therapeutic agent in an iontophoretic drug delivery device | Inactive | 14-Nov-2012 | ||
| WO-2012071175-A1 | User-activated self-contained co-packaged iontophoretic drug delivery system | Inactive | 23-Nov-2010 | ||
| CA-2779096-A1 | Methods for treating parkinson's disease | Inactive | 02-Nov-2009 | ||
| EP-2496080-A1 | Methods for treating parkinson's disease | Inactive | 02-Nov-2009 | A61K31/4985 |
NuPathe Signals
NuPathe Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Battelle Ventures | Venture Capital | Minority | ||
| Bay City Capital | Venture Capital | Minority | ||
| Ben Franklin Technology Partners of Southeastern Pennsylvania | Accelerator/Incubator | Minority | ||
| BioAdvance Capital (Conshohocken) | Venture Capital | Minority | ||
| Birchmere Ventures | Venture Capital | Minority |
NuPathe FAQs
-
When was NuPathe founded?
NuPathe was founded in 2005.
-
Where is NuPathe headquartered?
NuPathe is headquartered in Conshohocken, PA.
-
What is the size of NuPathe?
NuPathe has 14 total employees.
-
What industry is NuPathe in?
NuPathe’s primary industry is Drug Delivery.
-
Is NuPathe a private or public company?
NuPathe is a Private company.
-
What is the current valuation of NuPathe?
The current valuation of NuPathe is .
-
What is NuPathe’s current revenue?
The current revenue for NuPathe is .
-
How much funding has NuPathe raised over time?
NuPathe has raised $173M.
-
Who are NuPathe’s investors?
Battelle Ventures, Bay City Capital, Ben Franklin Technology Partners of Southeastern Pennsylvania, BioAdvance Capital (Conshohocken), and Birchmere Ventures are 5 of 11 investors who have invested in NuPathe.
-
Who are NuPathe’s competitors?
BioCryst Pharmaceuticals and Nabriva Therapeutics are competitors of NuPathe.
-
When was NuPathe acquired?
NuPathe was acquired on 24-Feb-2014.
-
Who acquired NuPathe?
NuPathe was acquired by Teva Pharmaceutical Industries.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process